Orgenesis Inc. (ORGS)

Orgenesis Inc. (ORGS) is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Orgenesis Inc. (ORGS) is not very popular among insiders. Orgenesis Inc. (ORGS) is a mediocre stock to choose.

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and prov...

News

Orgenesis Inc. (NASDAQ:ORGS) Short Interest Update

Zolmax Orgenesis Inc. (NASDAQ:ORGS - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 445,500 shares...\n more…

Orgenesis announces results for study of CD19 CAR-T therapy

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Globe Newswire Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult...\n more…

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Globe Newswire The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint...\n more…

ORGS Stock Earnings: Orgenesis Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nOrgenesis just reported results for the second quarter of 2024.\nThe post ORGS Stock Earnings: Orgenesis Reported Results for Q2 2024...\n more…